Source-grounded facts extracted from Enveric Biosciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Kevin M. Coveney was appointed as chief financial officer at Enveric Biosciences, Inc..
“On February 22, 2023, Kevin M. Coveney, 59, was appointed as the chief financial officer of Enveric Biosciences, Inc. (the “Company”) effective March 13, 2023 (the “Effective Date”).”
Enveric Biosciences, Inc. shareholders approved Ratification of the selection and appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022 at the 2022-10-28 meeting.
“For Against Abstain 826,728 27,656 2,063”
Enveric Biosciences, Inc. shareholders approved Non-binding advisory vote to approve the compensation of the Company’s named executive officers at the 2022-10-28 meeting.
“For Against Abstain Broker Non-Votes 178,176 68,125 1,771 608,375”
Enveric Biosciences, Inc. shareholders approved Election of seven directors at the 2022-10-28 meeting.
“Nominee For Withheld Broker Non-Votes George Kegler 138,269 109,803 608,375”
Robert Dickey IV was appointed as Chief Financial Officer at Enveric Biosciences, Inc..
“On September 9, 2022, Robert Dickey IV was appointed as the Chief Financial Officer (“CFO”) of the Company, to serve on an interim basis, effective September 9, 2022.”
Frank Pasqualone was appointed as Director at Enveric Biosciences, Inc..
“On July 13, 2022, Frank Pasqualone was appointed to the board of directors (the “Board”) of Enveric Biosciences, Inc. (the “Company”), to serve as a director of the Board, to fill a vacancy as a result of the increase in the size of the Board from eight to nine persons, effective as of the same date”
Bevin O'Neil was appointed as Director at Enveric Biosciences, Inc..
“On June 13, 2022, Mike Webb and Bevin O’Neil were appointed to the board of directors (the “Board”) of Enveric Biosciences, Inc.”
Mike Webb was appointed as Director at Enveric Biosciences, Inc..
“On June 13, 2022, Mike Webb and Bevin O’Neil were appointed to the board of directors (the “Board”) of Enveric Biosciences, Inc.”
Brad Thompson resigned as Director at Enveric Biosciences, Inc..
“On May 3, 2022, Brad Thompson, PhD resigned from the board of directors (the “ Board ”) of Enveric Biosciences, Inc. (the “ Company ”).”
Avani Kanubaddi was appointed as President at Enveric Biosciences, Inc..
“On November 15, 2021, Enveric Biosciences, Inc. (the “Company”) appointed Avani Kanubaddi, the Chief Operating Officer of the Company, to serve as the Company’s President, effective as of November 15, 2021.”
David Johnson changed role as Executive Chairman at Enveric Biosciences, Inc..
“assigned David Johnson, 63, the title of Executive Chairman of the Company, and removed the title of Chief Executive Officer.”
Brad Thompson was appointed as Director at Enveric Biosciences, Inc..
“the Company appointed each of (i) Dr. Joseph Tucker, who served as president and chief executive officer, and as a director, of MagicMed immediately prior to the Effective Time and (ii) Brad Thompson, who served as a director of MagicMed immediately prior to the Effective Time, to the Company’s board of directors”
Dr. Joseph Tucker was appointed as Director at Enveric Biosciences, Inc..
“the Company appointed each of (i) Dr. Joseph Tucker, who served as president and chief executive officer, and as a director, of MagicMed immediately prior to the Effective Time and (ii) Brad Thompson, who served as a director of MagicMed immediately prior to the Effective Time, to the Company’s board of directors”
Dr. Jillian Hagel was appointed as Chief Technology Officer at Enveric Biosciences, Inc..
“the Company appointed each of (i) Dr. Tucker, 53, (ii) Dr. Peter Facchini, 58 and (iii) Dr. Jillian Hagel, 43, to be Chief Executive Officer, Chief Scientific Officer and Chief Technology Officer, respectively”
Dr. Peter Facchini was appointed as Chief Scientific Officer at Enveric Biosciences, Inc..
“the Company appointed each of (i) Dr. Tucker, 53, (ii) Dr. Peter Facchini, 58 and (iii) Dr. Jillian Hagel, 43, to be Chief Executive Officer, Chief Scientific Officer and Chief Technology Officer, respectively”
Dr. Joseph Tucker was appointed as Chief Executive Officer at Enveric Biosciences, Inc..
“the Company appointed each of (i) Dr. Tucker, 53, (ii) Dr. Peter Facchini, 58 and (iii) Dr. Jillian Hagel, 43, to be Chief Executive Officer, Chief Scientific Officer and Chief Technology Officer, respectively”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.